Presentation (CTI)

OBJECTIVES: Globally, prostate cancer is the second leading cause of death for males and the most common kind of cancer. Although there are several methods for diagnosing and treating this kind of cancer, high-grade or locally advanced prostate tumors have the capacity to progress to a stage where they can be fatal. Precision medicine is a new and developing subject that is crucial to finding new illness subclassifications and offering therapy recommendations based on personal multi-omics data
METHODS: We systematically searched PubMed, Cochrane, ct.gov and evidence-based websites for publications with keywords like “precision medicine” and “prostate cancer” between 2014 and 2024 for review. We included studies that discuss immunotherapy, genomics, biomarker and diagnostic biomarker based precision medicine for prostate cancer
RESULTS: Through the literature it was found that precision medicine for prostate cancer may force improvements in clinical procedures through tactics like individual genetic profiling and focusing on certain disease pathways. Targeting gene fusions, genome editing tools, non-coding RNA biomarkers, and the potential of liquid tumor profiling are a few recent developments in prostate cancer precision medicine
CONCLUSIONS: Oncologists are using omics techniques including genomes, transcriptomics, proteomics, and metabolomics more and more to better understand cancer and find new biomarkers and treatment targets. There is potential for improving the diagnosis and treatment of this illness using targeted drugs that target genetic pathways and abnormalities